Drugs For Parkinson's Disease. History of Parkinson's Disease l First characterized in 1817 by James Parkinson : An Essay On The Shaking Palsy.

Slides:



Advertisements
Similar presentations
1 Adult Health II Neurological Diseases Jerry Carley RN, MSN, MA, CNE Summer, 2010.
Advertisements

Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
Parkinson's Disease Animal Models and Possible Treatments.
Diagnosis and Management of Parkinson’s Disease
ILOs At the end of this lecture you will be able to:- Recognize the symptoms and pathophysiology of parkinsonism. Understand the pharmacology of drugs.
ILOs At the end of this lecture you will be able to:- Revew the symptoms and pathophysiology of parkinsonism. Detail on the pharmacology of drugs used.
Parkinson’s Disease (PD)
Copyright © 2014 by Mosby, an imprint of Elsevier Inc.
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
Initial Diagnosis and Management of Parkinson’s Disease
Parkinson’s Disease Busra Berika Yucel
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
Objectives Description of Parkinson's disease
Drugs for Parkinon’s disease Parkinson's disease –progressive tremor –Bradykinesia and rigidity –degeneration of the dopaminergic nigrostriatal pathway.
Drugs of Anti-Parkinson’s disease Department of Pharmacology Zhang Yan-mei.
PARKINSON’S DISEASE. ETIOLOGY 1) Idiopathic 2)Exposure to : neurotoxin Oxidative stress Drugs Oxidative stress Drugs 3)Genetic factors. 3)Genetic factors.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Chapter 31 Anti-Parkinson Agents. Copyright 2007 Thomson Delmar Learning, a division of Thomson Learning Inc. All rights reserved Parkinson’s.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Drugs used in Parkinson disease. Epidemiology Average age of onset 62.5 Men and women affected equally Genetic Link African-Americans and Asians less.
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Represented by SHIVAJI SINGH SAMEER CHAVAN SOURIMA MUKHERJEE SONAL KULKARNI SUVARNA CHAVAN M.Sc (CLINICAL RESEARCH) (CRANFIELD)GROUP-9.
Slide 1 Copyright © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 13 Drugs Affecting the Autonomic Nervous System.
Slide 1 Mosby items and derived items © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 15 Drugs Used for Parkinson’s Disease.
Drugs used in parkinsonism
By Prof. Hanan Hagar Pharmacology unit Medical College.
By Prof. Hanan Hagar Pharmacology unit Medical College.
1 Copyright © 2012, 2009, 2006, 2003 by Saunders, an imprint of Elsevier Inc. Chapter 23 DRUGS FOR NEUROLOGIC DISORDERS: PARKINSONISM AND ALZHEIMER’S DISEASE.
Parkinson's Disease ILOs
Drugs in parkinsonism ilos
Dr. Laila M. Matalqah Ph.D. Pharmacology PHARMACOLOGY OF CNS part 1 General Pharmacology M212.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
CNS -Antiparkinsonian Drugs Discuss the signs and symptoms exhibited by a patient with Parkinson’s Disease Describe the actions and intended effects of.
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
 Parkinson’s disease is a neurodegenerative disorder first described by Dr James Parkinson, a London physician, in The underlying cause is loss.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Pharmacological Treatment of Parkinson Disease: A.
Pharmacologic Management of parkinsonism
Drugs used in Parkinson disease Historical Perspective Dr. James Parkinson ( ) 1817 “ involuntary tremulous motion ” “ pass from a walking.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Pharmacology Nursing C ONTINUE CNS D RUGS Lecture 7.
Drugs used in Parkinson’s disease
Parkinson's disease.
Drugs Used for Parkinson’s Disease
Parkinson’s Disease.
Parkinsonism.
MOVEMENT DISORDERS.
DRUGS FOR PARKINSONISM
Pharmacologic Management of Parkinson disease (PD)
Drugs for Neurologic Disorders: Parkinsonism and Alzheimer’s Disease
Drugs of Anti-Parkinson’s disease
Drugs used in parkinsonism
Central Nervous System Drugs: Part 1 Autonomic Nervous System Drugs Drugs Used to treat Seizures Drugs Used to treat Parkinson’s Disease Analgesics.
Drugs for Parkinson’s Disease
Treatment of Parkinson’s disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
Central Nervous System
Parkinsonism and Anesthesia
מחלת פרקינסון מחלת פרקינסון היא מחלה Progressive.
Anti-parkinsonism Drugs
Anti-parkinsonism Drugs
Introduction to Clinical Pharmacology Chapter 28 Antiparkinson Drugs
Drugs for Degenerative Diseases of the Nervous System
Chapter 17 Antiparkinson Drugs.
Neurodegenerative diseases
Presentation transcript:

Drugs For Parkinson's Disease

History of Parkinson's Disease l First characterized in 1817 by James Parkinson : An Essay On The Shaking Palsy

l Dr. Parkinson characterized the disease: l rigidity l tremor l mask face l stooped body posture l festinating gait

Epidemiology n The Real Cause Is Under Investigation l Loss of dopamine production and release in the basal ganglia

l Presence of persistent cholinergic output in the basal ganglia in the absence of dopaminergic influences

l Environmental Toxins - Possible Causes? l Manganese Workers In Chile l Tetrahydroisoquinoline (TIQ) - A Toxic Chemical Also Causes Parkinsonism

l N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) - A Toxic Chemical Causing Parkinsonism - Is Refractory To Treatment

Parkinsonian Drugs l Anticholinergic Agents l Dopaminergic Agents l Dopamine-Like Agents

Anticholinergic Drugs l Trihexyphenidyl HCl (Artane) l Benztropine Mesylate (Cogentin) l Biperiden HCl (Akineton) l Procyclidine HCl (Kemadrin) l Ethopropazine HCl (Parsidol) l Diphenhydramine HCl (Benadryl)

l Mainline Medications Until The Early 1960's l Now Are Used In A Supportive Role l Useful In Patients With Minimal Symptoms

l Useful In Patients Who Cannot Tolerate Levodopa l Useful In Patients In Whom Levodopa Does Not Appear Effective

Mechanism Of Action l Mainly Controls Salivation and Drooling l Anticholinergics Blunt Excitatory Effects Of Acetylcholine l Anticholinergics Competitively Block The Adrenergic Receptors Thus Reduce The Effects Of Acetylcholine

Adverse Side Effects Of Anticholinergics l Tachycardia l Photosensitivity Of The Skin l Constipation l Urinary Retention l Psychiatric Disturbances

l Dry Mouth (Xerostomia) l Blurred Vision l Pupillary Dilatation (Mydriasis) l Hallucinations l Confusion

Dopaminergic Drugs u True Dopamine Medications l Levodopa (Larodopa, Levodopa) l Carbidopa-Levodopa (Sinemet)

The Problem With Levodopa l When Levadopa is taken orally, it is changed in the gut into dopamine by an enzyme called dopa decarboxylase.

l Herein lies the problem ….. Dopamine cannot cross the blood-brain barrier. So, it is useless to the Parkinson’s patient if it never gets into the brain !!

l So….. the key is to keep levadopa as levadopa until it reaches the blood-brain barrier. l How do we keep levadopa from being converted to dopamine ?

l You have to combine levadopa with a dopa decarboxylase inhibitor to insure that levadopa gets to and can cross over the blood-brain barrier.

l Carbidopa is the name of the dopa decarboxylase inhibitor that is combined with levadopa which enables levadopa to get to and cross over the blood-brain barrier l This medication combination is called Sinemet

l At the blood-brain barrier, carbidopa is cleaved from levadopa. l Levadopa than easily crosses over the blood-brain barrier into the brain.

l In the brain, levadopa is converted to dopamine where it exerts its inhibitory effects and calms the tremors, and other symptoms of Parkinson’s Disease

Medical Uses Treat The Symptomatology Treat The Symptomatology l To Improve Fine Motor Control l To Improve Gross Motor Control & Balance During Ambulation

l To Decrease Tremor, Rigidity, Bradykinesia l Improve Speech l Improve Handwriting l Improve Swallowing l Normalization Of Respiratory Movement

Adverse Side Effects u Levodopa u Tachycardia - Dopamine has beta- 1 effects on the cardiovascular system u Postural Hypotension - Is lessened when Levodopa is taken with Carbidopa (Sinemet)

l Tics l Spasms l Ballistic Movements

l Behavioral Changes l Depression, Manic Behavior, Anxiety Attacks, Confusion, Hallucinatory Behaviors l May Require A Drug Holiday

Dopamine-Like Drugs l Amantadine HCl (Symmetrel)

Amantadine Mechanism Of Action u This Medication Is An Antiviral Medication u Its Mechanism Of Action Is Unknown l Believed to facilitate release of dopamine from storage sites in the basal ganglia

Adverse Side Effects l Orthostatic Hypotension l Nightmares l Confusion l Depression l Hallucinatory Behavior

Dopamine-Like Drugs l Bromocriptine Mesylate (Parlodel) l Pergolide Mesylate (Permax)

l These Medications Are Ergot Alkaloids & Belong To The Same Family As LSD

l These Medications Are Used To Decrease The Untoward Side Effects Seen In Patients Using Levodopa - i.e. Involuntary Movements

Ergolines : Adverse Side Effects l Nausea l Vomiting l Postural Hypotension l Visual and Auditory Hallucinations l Livedo Reticularis - Purple Discoloration Of The Skin

Dopamine-Like Drugs l Selegiline HCl (Eldepryl)

Selegiline Mechanism Of Action l This Medication Is A Monoamine Oxidase (MAO) Inhibitor l It inhibits MAO, the enzyme which destroys dopamine l Selegiline prolongs the biological half-life of dopamine

l This Medication Is More Effective When Given To New Parkinson's Patients

l Selegiline allows the patient to: l Take a lower dose of Levodopa l Lengthens out the dosing intervals l Side effects are insignificant

Selegiline : Adverse Reactions n Nausea & Vomiting n Orthostatic Hypotension *** n Fainting & Dizziness *** n Hallucinations *** n Loss Of Balance & Syncope *** n Depression

Dopamine-Like Drugs n Pramipexole (Mirapex) n Ropinrole (Requip)

Mechanism Of Action n Mechanism is not exactly clear u Stimulates the dopamine receptors of the Corpus Striatum

Adverse Side Effects n Drowsiness n Orthostatic Hypotension n Hallucinations n Dizziness n Syncope

Clinical Considerations l Schedule The Rehab Session One Hour After The Morning Dose l The patients will be rested from the night's sleep l The drug will be at its peak effectiveness

n Maintain Joint Range Of Motion During A Drug Holiday

l Maintain As Much Cardiovascular Fitness As Possible During The Drug Holiday l Monitor The Patient's Blood Pressure - Orthostatic Hypotension l Be Aware Of The Patient's Balance & Gross Motor Control - Protect Against Falling